NCT04307082View on ClinicalTrials.gov

ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

June 30, 2020

Conditions
Fungal Infection
Interventions
DRUG

[14C]-Ibrexafungerp

Radio-labeled Ibrexafungerp, single dose.

Trial Locations (1)

NG116Js

Quotient Sciences, Nottingham

Sponsors

Collaborators (1)

Inncelerex
All Listed Sponsors
collaborator

Inncelerex

UNKNOWN

lead

Scynexis, Inc.

INDUSTRY

NCT04307082 - ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Biotech Hunter | Biotech Hunter